MACI IS PROVEN IN CLINICAL STUDIES

SUMMIT TRIAL:
2-year study of MACI vs. microfracture: improvements in pain and function1

Mean Patient-Reported KOOS Scores at Year 2 and Year 5

In the SUMMIT trial, a significantly greater proportion of patients treated with MACI experienced clinically meaningful improvements in both pain and function at 2 years when compared to microfracture1

In a follow-up extension study, improvements in pain and function at Year 2 were maintained at Year 52

 

clinical experience 

In a responder analysis, the proportion of subjects with at least a 10-point improvement in both KOOS Pain and Function (SRA) was greater in the MACI group (63/72=87.5%; 95% CI [77.6%, 94.1%]) compared with the microfracture group (49/72=68.1%; 95% CI [56.0%, 78.6%]).1

MACI unlocks the potential of your patient's own cells.
See the science behind MACI

1. Saris D, Price A, Widuchowski W, et al. for the SUMMIT study group. Matrix-applied characterized autologous cultured chondrocytes versus microfracture: two-year follow-up of a prospective randomized trial. Am J Sports Med. 2014;42:1384-1394.

2. Brittberg M, Recker D, Ilgenfritz J, Saris D. SUMMIT Extension Study Group. Matrix-applied characterized autologous cultured chondrocytes versus microfracture: Five-year follow-up of a prospective randomized trial. Am J Sports Med. 2018;46(6):1343-1351.

PP.US.MAC.1015 v1.0